1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
193.97 USD   -1.36%
08/10BEIGENE : Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer - Form 8-K
PU
08/10BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/10Asian ADRs Move Sharply Higher in Wednesday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)

06/30/2022 | 04:19pm EDT

Item 8.01. Other Events.


On June 30, 2022, BeiGene, Ltd. ("BeiGene") announced new data from RATIONALE
306, a global Phase 3 trial evaluating tislelizumab plus chemotherapy in adult
patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC)
without prior systemic treatment for advanced disease, presented as a
late-breaking oral presentation at the 2022 European Society for Medical
Oncology (ESMO) World Congress on Gastrointestinal Cancer. The full text of this
press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.


Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

   Exhibit No.            Description

       99.1               Press release titled "BeiGene Announces

Late-Breaking Data at ESMO GI

                          Showing Overall Survival Benefit for Tislelizumab 

Plus Chemotherapy in

                          First-Line Advanced or Metastatic Esophageal 

Squamous Cell Carcinoma" issued

                          by BeiGene, Ltd. on June 30, 2022

       104                The cover page from this Current Report on Form 

8-K, formatted in Inline

                          XBRL



--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about BEIGENE, LTD.
08/10BEIGENE : Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab ..
PU
08/10BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/10Asian ADRs Move Sharply Higher in Wednesday Trading
MT
08/09JPMorgan Assumes BeiGene at Overweight with $296 Price Target
MT
08/09Novartis-BeiGene Liver Cancer Drug Works As Well As Bayer's Nexavar in Phase 3 Study
MT
08/09BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab..
BU
08/09BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab..
CI
08/08BEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
08/08Nomura Adjusts BeiGene's Price Target to $286.31 From $277.35, Maintains Buy Rating
MT
08/08Nomura Adjusts Beigene's Price Target to HK$172.89 From HK$167.48, Keeps at Buy
MT
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations